A011-13 HYPERION A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial
Hypertension (PAH) Therapy in Newly Diagnosed Intermediate-and High-risk PAH Patients

NCT04811092

HYPERION A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial
Hypertension (PAH) Therapy in Newly Diagnosed Intermediate-and High-risk PAH Patients

Associated Conditions

Pulmonary Hypertension

Principal Investigator

Sponsor

Acceleron

Pulmonary arterial hypertension (PAH) is a disease affecting the blood vessels of the lungs. PAH leads to increased pressure in the blood vessels of the lungs which further leads to straining of the right side of the heart.
You are being asked to take part in a research study of an experimental treatment called sotatercept. “Experimental” means that sotatercept is currently being tested and is not approved for sale by any Health Authorities/regulatory agencies, such as the Food and Drug Administration (FDA), in any country.

This study is currently enrolling.